- Home
- DIAX vs EBS Comparison
DIAX vs EBS Comparison
Compare DIAX & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DIAX | EBS |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.0M | 625.0M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | DIAX | EBS |
|---|---|---|
| Price | $14.97 | $12.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 96.6K | ★ 840.6K |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 7.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | ★ $788,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.21 |
| P/E Ratio | ★ N/A | $9.04 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.80 | $4.02 |
| 52 Week High | $15.12 | $13.41 |
Technical Indicators
Market Signals| Indicator | DIAX | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 62.62 |
| Support Level | $14.81 | $12.06 |
| Resistance Level | $15.31 | $12.28 |
| Average True Range (ATR) | 0.13 | 0.55 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 27.89 | 78.39 |
Price Performance
Historical ComparisonAbout DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.